Andres Tellez, Ph.D.

  /  

Andres Tellez, Ph.D.

Senior Director of Business Development and Strategy

Andres Tellez comes to Cedilla from Syros Pharmaceuticals, where he served as senior director of business development and helped secure the company’s partnerships with Incyte and Johnson and Johnson. Before joining Syros, Andres worked for several years at Cerulean Pharma, rising to director and acting head of business development. At Cerulean he served in a broad role, advancing strategic collaborations and supporting the company’s clinical development and fundraising efforts. Andres has a Ph.D. in biomedical informatics from Stanford University and an SB and M.Eng in EECS from MIT.

C. Eric Schwartz, Ph.D.

  /  

C. Eric Schwartz, Ph.D.

Vice President, Drug Discovery

Eric Schwartz brings more than two decades of experience in drug discovery and development to Cedilla. He started his industry career in 1990 at Eisai Research Institute and later moved to positions of increasing responsibility at UCB Pharma, Biogen Idec, and Resolvyx Pharmaceuticals. In 2011 he joined Avila Therapeutics, which was acquired the following year by Celgene, where he served as executive director of chemistry until joining the team at Cedilla in May 2018. Eric received his B.S. degree from Ohio State University, completed his Ph.D. with Ed Vedejs at the University of Wisconsin-Madison, and followed that with a post-doctoral stint at the University of Pittsburgh in Dennis Curran’s group.

Véronique Riethuisen

  /  

Véronique Riethuisen

Chief Business Officer & Head of Finance

Véronique Riethuisen brings over 25 years of experience in global business development, M&A and alliance management leadership to Cedilla.  Most recently, Véronique served as Senior Vice President, Global Business Development and Strategic Alliance Management at Ipsen where she helped build Ipsen’s rare disease franchise by acquiring and licensing multiple innovative assets for the treatment of fibrodysplasia ossificans progressiva. Prior to Ipsen, Véronique was Vice President, Head of Global Transactions at Takeda where she led the BD team that transformed the company’s gastrointestinal and regenerative medicine portfolios. Earlier, Véronique held various business development, M&A and alliance management roles of increasing responsibility at Pfizer, Teva, Bristol Myers Squibb and Monsanto.  Véronique currently serves as an Executive Coach for the Mass NextGen program mentoring first-time female chief executive officers, and she also teaches a Business Development Fundamentals course offered annually in conjunction with the BIO Annual Conference.  Véronique holds a bachelor and master’s degree in Applied Economics from the University of Brussels (ULB), Belgium.

Christopher Lindblom

  /  
chris-lindblom

Christopher Lindblom

Vice President of Finance

Christopher M. Lindblom joined Cedilla Therapeutics as Vice President of Finance in July 2021. Chris’ 19-year biotech career spans both public and private biotech companies from driving long-range financial plans in concert with strategic planning to playing a key role in helping biotech companies raise capital, from confidential follow-on offerings for public companies to private equity rounds and venture debt deals. He is also experienced in executing mergers and acquisitions, as well as ensuring productive R&D and commercial collaborations. His other key responsibilities have included budgeting and forecasting, accounting and financial reporting (including for the SEC), tax planning and compliance, treasury and corporate insurance.  

Prior to joining Cedilla Therapeutics, Chris served as Vice President of Finance at IFM Therapeutics, Cogen Immune Medicine (up through its merger with Torque Therapeutics to form Repertoire Immune Medicines) and Warp Drive Bio (up through its acquisition by Revolution Medicines).  Chris held various senior finance roles for the first 11+ years in biotech at Millennium Pharmaceuticals, including the commercial launch of VELCADE®, and at Infinity Pharmaceuticals.  Chris also served as Vice President of Finance at Ovascience and as Senior Vice President of Finance and Administration at BIND Therapeutics.  

Chris obtained his MBA from Boston College and B.S. in Accounting from Syracuse University. Chris is a certified public accountant and started his career at PricewaterhouseCoopers. 

Alexandra Glucksmann, Ph.D.

  /  

Alexandra Glucksmann, Ph.D.

President and Chief Executive Officer

Sandra Glucksmann is a veteran biopharma executive and experienced scientist who most recently served as founder and chief operating officer of the gene editing company Editas Medicine, Inc. She previously served as senior vice president of research and development at Cerulean Pharma, which she also joined at its founding. Sandra was a founding scientist at Millennium Pharmaceuticals, where she spent 13 years, taking on a series of senior roles on the science team before moving into an executive position with responsibility for strategic program management and operations. Sandra serves on the boards of directors of gene therapy company REGENXBIO and Scenic Biotech. Sandra holds a Ph.D. with honors in molecular genetics and cell biology from the University of Chicago. She was a post-doctoral fellow at MIT.

Brian Jones, Ph.D.

  /  

Brian Jones, Ph.D.

Chief Scientific Officer

Brian Jones has more than 25 years of drug discovery experience and has led the molecular discovery behind more than 20 INDs across several therapeutic areas. Most recently he spent 11 years at Novartis, where he was head of discovery chemistry for NIBR in Cambridge, Mass. Prior to that, Brian was at Merck for 16 years, initially as director of medicinal chemistry in Rahway, N.J. and subsequently as senior director at the Neuroscience Research Centre in the UK. Brian holds a Ph.D. in chemistry from Imperial College, London. He was a NATO post-doctoral fellow at Yale University.

Iván Cornella-Taracido, Ph.D.

  /  

Iván Cornella-Taracido, Ph.D.

Vice President, Proteomics and Chemical Biology

Iván Cornella-Taracido joins Cedilla from Merck Research Laboratories, where he was the director of chemical biology. Prior to Merck, Iván held leadership positions at AstraZenca, where he established and managed the global chemical biology team; Sanofi, where he founded the chemical genetics and proteomics team; and Novartis, where he was a founding member of the small molecule target identification and mode of action elucidation (TIDMoA) platform. Iván has a B.Sc. in chemistry, an M.Sc. in organic chemistry and a Ph.D. in organic chemistry from the Universidade da Coruña in Spain. He completed postdoctoral work at the Institute of Chemistry & Cell Biology of Harvard Medical School (now the Broad Institute of MIT and Harvard) and in the Boston College chemistry department.

Delphine Collin, Ph.D.

  /  

Delphine Collin, Ph.D.

Vice President, Biomolecular Sciences

Delphine Collin joins Cedilla from HarkerBIO, where she served as their chief innovation officer. Prior to HarkerBIO, she served as senior principal scientist at Boehringer Ingelheim (BI) and led a biophysics group focused on lead identification and optimization in the small molecule drug discovery group. While at BI, Delphine also started her own consulting firm, Delphine Collin Consulting, LLC., where she supported companies with specialized biophysical approaches to drug discovery. Prior to BI, Delphine was a research fellow at Merck & Co. Delphine holds a Ph.D. in biophysical chemistry and doctorate in pharmaceutical sciences from the University of Paris XI, France.

Justin Birtz

  /  

Justin Birtz

Vice President, People and Culture

Justin Birtz brings to Cedilla nearly two decades of talent and organizational development experience. Justin joins Cedilla from BitSight, where he was director, people operations. There, Justin designed and developed the company’s first programs in leadership development, new leader onboarding and performance management with the goal of evolving company culture and inspiring new ways of thinking. Prior to BitSight, Justin was director, HR business partnership and director, learning and organizational development at iRobot. Previously, Justin spearheaded growth initiatives as an HR manager at Imprivata, Teladoc and Symbotic. He holds a master’s degree in human resource management from Framingham State University and a bachelor’s degree in management from Isenberg School of Management, University of Massachusetts at Amherst.